Exhibition Invitation | May 25-26 CIS-Asia 2023 14th Annual ChemPharma International Summit - Asia, you are warmly invited to stop by booth 36!


Dear friends and partners,


      Thank you for your continuous support and firm recognition! Linkchem will take part in the CIS-Asia 2023 14th Annual ChemPharma International Summit - Asia. We cordially invite you to come to our booth to talk about the development of CMC innovative drugs and the industry.

Date: May 25 - 26, 2023 

Location: Suzhou Shishan International Convention Center, China

Organizers: Best Media, Chinese Pharmaceutical Association Pharmaceutical Engineering Professional Committee

Booth No.: 36

Meanwhile, you are also welcome to attend our keynote speech from 14:50 to 15:30 on March 25.


Speech Topic:

Design, Selection, Optimization and Innovation of Small Molecule New Drug Synthesis

Date & Time:

March 17 from 14:50 to 15:30

(Forum 2)


Yongli Zhong


Vice President and Chief Technology Officer(CTO)

Dr. Zhong joined Linkchem in October 2022, and is the vice president and chief technology officer (CTO) of the company. He graduated from the Department of Chemistry, Sun Yat-sen University with a B.Sc. and a M.Sc. in organic chemistry, and taught for many years, during which he won two collective awards: Guangdong Province University Prize for Progress in Science, and Guangdong Province Second Prize Award in Natural Science. From 1995 to 1998, he obtained a Ph.D. in organic chemistry under the supervision of Professor Shing, Kung Ming Tony, Department of Chemistry, at the Chinese University of Hong Kong. In 1998, he was invited by Professor K. C. Nicolaou and completed Postdoc at UC San Diego, Scripps Research Institute until mid-2001. Dr. Zhong served at Merck's Research and Development Process in Rahway, New Jersey, USA since June 2001. He successively held the positions of Senior Scientist, Research Scientist and Principal Scientist, engaging in the design, research and development, optimization and commercialization of small molecule drug synthesis routes.


In Merck’s 21-year process research and development career, Dr. Zhong was one of the key contributors to the design and development of commercial synthetic routes for 4 marketed drugs, Isentress, Grazoprevir, Relenactam and Vibegron, and led the design, development and production of a large number of API GMP routes for Merck’s drug candidates (all stages ranging from PCC to pre-commercial production). He has published over 90 scientific papers, 3 book chapters and filed 20 invention patents. Dr. Zhong has a strong industry background, outstanding innovation ability and rich experience in drug synthesis process design, development and management.


Linkchem will set up a booth during this conference. You can speak face-to-face with our scientists and business team. To schedule a meeting, please send an email to qihao.tang@linkchem.cn, sales@linkchem.cn. We will be in touch with you as soon as we receive your information!